XOMAO News and Press, XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock From 12/29/23

2023-12-29 07:00:00 ET Summary XOMA Corporation specializes in financing new drug development and offers preferred stocks as investment options. XOMA's strategy involves acquiring economic rights to future milestones and royalty payments associated with partnered pre-commercial cl...

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO ® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabi...

2023-12-15 08:30:00 ET Summary Preferred shares present a desirable trifecta of high yields, lower risk, and significant capital upside. At these bargain prices, preferred stocks have something for value, income, and growth investors. We discuss two +9% yielding preferreds for...

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple...

EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug App...

EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12, 202...

2023-09-01 07:30:00 ET Summary XOMA Corporation helps fund drug research and clinical trials in exchange for payments. Developing a new drug is expensive and high-risk, with a 90% failure rate in clinical trials. Along with its no-dividend Common, XOMA offers two preferred stocks ...

Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from commercial sales Company expects at least one partner to file a New Drug Applicati...

2023-06-26 03:13:41 ET The biotech royalty aggregator, XOMA ( NASDAQ: XOMA ) has been added to the Russell 2000 and Russell 3000 Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. XOMA is a...

EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000 ® and Russell 3000 ® Indexes following its annual reconstitution, which took effect after the U.S. markets close...